Cardiol Therapeutics Inc Class A (CRDL)
$1.06
$0.01
(0.95%)
As on 16-Jun-2026 16:00EDT
Market cap
$119 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
6.9
Div. Yield
0 %
Quality Score
/10
Growth Score
/10
Valuation Score
/10
Momentum Score
/10
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-1.7 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
0.3
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-0.4
-
Face value
--
-
Shares outstanding
115,272,240
7 Years Aggregate
CFO
CA$-108.70 Mln
EBITDA
CA$-167.55 Mln
Net Profit
CA$-142.58 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Cardiol Therapeutics Inc Class A (CRDL)
| 11.1 | -19.7 | 3.9 | -27.4 | 10.2 | -15.8 | -- |
|
BSE Sensex*
| -8.9 | 2.5 | 2.2 | -5.7 | 6.8 | 8.0 | 11.3 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2023
|
2022
|
2021
|
2020
|
|---|---|---|---|---|---|
|
Cardiol Therapeutics Inc Class A (CRDL)
| -25.5 | 65.3 | -72.4 | -33.5 | -39.3 |
|
S&P Small-Cap 600
| 4.0 | 13.9 | -17.4 | 25.3 | 9.6 |
|
BSE Sensex
| 9.1 | 18.7 | 4.4 | 22.0 | 15.8 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Cardiol Therapeutics Inc Class A (CRDL)
|
1.1 | 118.7 | 0.0 | -36.4 | -- | -215.1 | -- | 6.9 |
| 3.3 | 34.2 | 0.0 | -11.6 | -- | -19.7 | -- | 0.6 | |
| 3.0 | 188.3 | 321.4 | -122.1 | 5.7 | -22.7 | -- | 0.5 | |
| 1.0 | 449.1 | 306.1 | -349.9 | -99.7 | -45.8 | -- | 0.8 | |
| 0.3 | 2.1 | 44.1 | -11.1 | -15.1 | -- | -- | 0.9 | |
| 1.8 | 95.5 | 24.5 | -30.2 | -138.5 | -105.1 | -- | 5.6 | |
| 1.0 | 149.2 | 274.1 | -25.2 | -5.2 | -7 | -- | 0.6 | |
| 3.6 | 24.5 | 0.0 | -26.2 | -- | -284.6 | -- | 40.9 | |
| 3.6 | 24.5 | 0.0 | -31.0 | -- | -652.1 | -- | 40.9 | |
| 1.4 | 369.6 | 937.4 | -11.0 | -0.7 | -1 | -- | 0.5 |
Shareholding Pattern
View DetailsAbout Cardiol Therapeutics Inc Class A (CRDL)
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III... multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38, a novel subcutaneously administered drug formulation of cannabidiol for the treatment of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada. Read more
-
President, CEO & Director
Mr. David G. Elsley MBA
-
President, CEO & Director
Mr. David G. Elsley MBA
-
Headquarters
Oakville, ON
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Cardiol Therapeutics Inc Class A (CRDL)
What is the current share price of Cardiol Therapeutics Inc Class A (CRDL) Today?
The share price of Cardiol Therapeutics Inc Class A (CRDL) is $1.06 (NASDAQ) as of 16-Jun-2026 16:00 EDT. Cardiol Therapeutics Inc Class A (CRDL) has given a return of 10.18% in the last 3 years.
What is the current PB & PE ratio of Cardiol Therapeutics Inc Class A (CRDL)?
Since, TTM earnings of Cardiol Therapeutics Inc Class A (CRDL) is negative, P/E ratio is not available.
The P/B ratio of Cardiol Therapeutics Inc Class A (CRDL) is 6.94 times as on 12-Jun-2026, a 115 premium to its peers’ median range of 3.23 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-2.45
|
4.64
|
|
2024
|
-2.51
|
3.73
|
|
2023
|
-2.54
|
1.91
|
|
2022
|
-1.41
|
0.83
|
|
2021
|
--
|
--
|
What is the 52 Week High and Low of Cardiol Therapeutics Inc Class A (CRDL)?
The 52-week high and low of Cardiol Therapeutics Inc Class A (CRDL) are Rs 1.71 and Rs 0.88 as of 17-Jun-2026.
What is the market cap of Cardiol Therapeutics Inc Class A (CRDL)?
Cardiol Therapeutics Inc Class A (CRDL) has a market capitalisation of $ 119 Mln as on 12-Jun-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Cardiol Therapeutics Inc Class A (CRDL)?
Before investing in Cardiol Therapeutics Inc Class A (CRDL), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.